BR112017017888A2 - derivados fluorados do ácido tetraidronaftiridinil nonanoico derivados e usos destes - Google Patents
derivados fluorados do ácido tetraidronaftiridinil nonanoico derivados e usos destesInfo
- Publication number
- BR112017017888A2 BR112017017888A2 BR112017017888A BR112017017888A BR112017017888A2 BR 112017017888 A2 BR112017017888 A2 BR 112017017888A2 BR 112017017888 A BR112017017888 A BR 112017017888A BR 112017017888 A BR112017017888 A BR 112017017888A BR 112017017888 A2 BR112017017888 A2 BR 112017017888A2
- Authority
- BR
- Brazil
- Prior art keywords
- derivatives
- tetrahydronaphthyridinyl
- fluorinated
- nonanoic acid
- compounds
- Prior art date
Links
- SBSVVCSSIIMTQL-UHFFFAOYSA-N N1(CCCC2=CC=CN=C12)C(C(=O)O)CCCCCCC Chemical class N1(CCCC2=CC=CN=C12)C(C(=O)O)CCCCCCC SBSVVCSSIIMTQL-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 208000001344 Macular Edema Diseases 0.000 abstract 2
- 206010025415 Macular oedema Diseases 0.000 abstract 2
- 201000010230 macular retinal edema Diseases 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 206010012688 Diabetic retinal oedema Diseases 0.000 abstract 1
- 206010012689 Diabetic retinopathy Diseases 0.000 abstract 1
- 206010016654 Fibrosis Diseases 0.000 abstract 1
- 201000011190 diabetic macular edema Diseases 0.000 abstract 1
- 230000004761 fibrosis Effects 0.000 abstract 1
- 208000002780 macular degeneration Diseases 0.000 abstract 1
- 210000001957 retinal vein Anatomy 0.000 abstract 1
- 230000002194 synthesizing effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/70—One oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562118303P | 2015-02-19 | 2015-02-19 | |
| PCT/US2016/018612 WO2016134223A2 (en) | 2015-02-19 | 2016-02-19 | Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112017017888A2 true BR112017017888A2 (pt) | 2018-04-10 |
Family
ID=56689184
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112017017888A BR112017017888A2 (pt) | 2015-02-19 | 2016-02-19 | derivados fluorados do ácido tetraidronaftiridinil nonanoico derivados e usos destes |
Country Status (13)
| Country | Link |
|---|---|
| US (5) | US9790222B2 (https=) |
| EP (2) | EP3925959A1 (https=) |
| JP (2) | JP2018510139A (https=) |
| KR (1) | KR102647026B1 (https=) |
| CN (2) | CN114805342A (https=) |
| AU (1) | AU2016219906B2 (https=) |
| BR (1) | BR112017017888A2 (https=) |
| CA (1) | CA2976634C (https=) |
| ES (1) | ES2892954T3 (https=) |
| IL (1) | IL253873A0 (https=) |
| RU (1) | RU2017132433A (https=) |
| TW (1) | TWI736529B (https=) |
| WO (1) | WO2016134223A2 (https=) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8901144B2 (en) * | 2013-02-07 | 2014-12-02 | Scifluor Life Sciences, Llc | Fluorinated 3-(2-oxo-3-(3-arylpropyl)imidazolidin-1-yl)-3-arylpropanoic acid derivatives |
| PT2953948T (pt) | 2013-02-07 | 2017-12-12 | Scifluor Life Sciences Inc | Antagonistas de integrina fluorada |
| GB201305668D0 (en) | 2013-03-28 | 2013-05-15 | Glaxosmithkline Ip Dev Ltd | Avs6 Integrin Antagonists |
| GB201417018D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| GB201417094D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| GB201417011D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| GB201417002D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compound |
| US9790222B2 (en) * | 2015-02-19 | 2017-10-17 | Scifluor Life Sciences, Inc. | Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and uses thereof |
| WO2016154369A1 (en) * | 2015-03-26 | 2016-09-29 | Merck Sharp & Dohme Corp. | Composition and methods for treating chronic kidney disease |
| BR112017023432A2 (pt) * | 2015-04-30 | 2018-07-24 | Scifluor Life Sciences Inc | Derivados de ácido propiônico tetra- hidronaftiridinila e usos do mesmo |
| GB201604680D0 (en) | 2016-03-21 | 2016-05-04 | Glaxosmithkline Ip Dev Ltd | Chemical Compounds |
| US10118929B2 (en) | 2016-04-27 | 2018-11-06 | Scifluor Life Sciences, Inc. | Nonanoic and decanoic acid derivatives and uses thereof |
| EP3509590A4 (en) | 2016-09-07 | 2020-12-02 | Pliant Therapeutics, Inc. | N-ACYL AMINO ACID COMPOUNDS AND METHODS OF USE |
| HRP20210228T1 (hr) | 2016-11-08 | 2021-03-19 | Bristol-Myers Squibb Company | Amidi pirola kao inhibitori alfa v integrina |
| ES2984394T3 (es) * | 2016-11-08 | 2024-10-29 | Bristol Myers Squibb Co | Compuestos mono y espirocíclicos que contienen ciclobutano y azetidina como inhibidores de la integrina alfa v |
| BR112019009245A2 (pt) | 2016-11-08 | 2019-07-16 | Bristol-Myers Squibb Company | azol amidas e aminas como inibidores de alfav integrina |
| WO2018089357A1 (en) | 2016-11-08 | 2018-05-17 | Bristol-Myers Squibb Company | INDAZOLE DERIVATIVES AS αV INTEGRIN ANTAGONISTS |
| AU2017359023B2 (en) | 2016-11-08 | 2021-12-09 | Bristol-Myers Squibb Company | 3-substituted propionic acids as alpha v integrin inhibitors |
| MA52117A (fr) | 2017-02-28 | 2022-04-06 | Morphic Therapeutic Inc | Inhibiteurs de l'intégrine (alpha-v) (bêta-6) |
| MX394210B (es) | 2017-02-28 | 2025-03-04 | Morphic Therapeutic Inc | INHIBIDORES DE INTEGRINA AVß6. |
| WO2018183795A1 (en) * | 2017-03-30 | 2018-10-04 | Scifluor Life Sciences, Inc. | Method of making tetrahydronaphthyridinyl nonanoic acid compounds |
| KR102700471B1 (ko) | 2017-11-07 | 2024-08-28 | 브리스톨-마이어스 스큅 컴퍼니 | 알파 v 인테그린 억제제로서의 피롤로피라진 유도체 |
| SG11202009734VA (en) * | 2018-04-27 | 2020-11-27 | Arrowhead Pharmaceuticals Inc | Integrin targeting ligands and uses thereof |
| WO2020047239A1 (en) | 2018-08-29 | 2020-03-05 | Morphic Therapeutic, Inc. | INHIBITING αV β6 INTEGRIN |
| SI3844162T1 (sl) * | 2018-08-29 | 2025-06-30 | Morphic Therapeutic, Inc. | Zaviralci integrina alfa v beta6 |
| WO2020047208A1 (en) | 2018-08-29 | 2020-03-05 | Morphic Therapeutic, Inc. | Inhibitors of (alpha-v)(beta-6) integrin |
| CN115989235A (zh) * | 2020-05-07 | 2023-04-18 | 普利安特治疗公司 | 使用氨基酸化合物治疗呼吸系统疾病的方法 |
| WO2021231581A1 (en) | 2020-05-12 | 2021-11-18 | Scifluor Life Sciences, Inc. | METHODS OF TREATING OR PREVENTING VIRAL INFECTION WITH FLUORINATED α V INTEGRIN ANTAGONISTS |
| US20230398061A1 (en) * | 2020-10-20 | 2023-12-14 | The Board Of Trustees Of The Leland Stanford Junior University | Injectable hydrogels for adoptive cell therapy |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4927266A (en) | 1987-03-30 | 1990-05-22 | Anritsu Corporation | Optical signal generating apparatus and optical power meter calibrating system using the same |
| CA1318254C (en) | 1988-01-06 | 1993-05-25 | Munehiro Tomikawa | Inhibitory agent of hepatic fibrosis containing pantethine |
| ES2104938T3 (es) | 1991-04-01 | 1997-10-16 | Univ Duke | Metodo de inhibir la fibrosis. |
| US5501969A (en) | 1994-03-08 | 1996-03-26 | Human Genome Sciences, Inc. | Human osteoclast-derived cathepsin |
| JP3818322B2 (ja) | 1994-04-28 | 2006-09-06 | 敏一 中村 | コラーゲン分解促進剤 |
| US6544767B1 (en) | 1994-10-27 | 2003-04-08 | Axys Pharmaceuticals, Inc. | Cathespin O2 protease |
| US5736357A (en) | 1994-10-27 | 1998-04-07 | Arris Pharmaceutical | Cathespin O protease |
| US5645839A (en) | 1995-06-07 | 1997-07-08 | Trustees Of Boston University | Combined use of angiotensin inhibitors and nitric oxide stimulators to treat fibrosis |
| US6664227B1 (en) | 1996-03-01 | 2003-12-16 | Genetics Institute, Llc | Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor chains |
| US6211184B1 (en) | 1996-08-29 | 2001-04-03 | Merck & Co., Inc. | Integrin antagonists |
| WO1998008528A1 (en) | 1996-08-30 | 1998-03-05 | Biomeasure Incorporated | Method of inhibiting fibrosis with a somatostatin agonist |
| CA2315370A1 (en) | 1997-12-17 | 1999-06-24 | Merck & Co., Inc. | Integrin receptor antagonists |
| US6017926A (en) | 1997-12-17 | 2000-01-25 | Merck & Co., Inc. | Integrin receptor antagonists |
| EA003095B1 (ru) * | 1997-12-17 | 2002-12-26 | Мерк Энд Ко., Инк. | Антагонисты рецепторов интегринов |
| CN1284955A (zh) | 1997-12-17 | 2001-02-21 | 麦克公司 | 整联蛋白受体拮抗剂 |
| US6066648A (en) | 1997-12-17 | 2000-05-23 | Merck & Co., Inc. | Integrin receptor antagonists |
| US6048861A (en) | 1997-12-17 | 2000-04-11 | Merck & Co., Inc. | Integrin receptor antagonists |
| KR20010033248A (ko) | 1997-12-17 | 2001-04-25 | 폴락 돈나 엘. | 인테그린 수용체 길항제 |
| US6117445A (en) | 1998-01-28 | 2000-09-12 | Link Technology Inc. | Methods for the prevention and treatment of fibrosis and sclerosis |
| US6420396B1 (en) * | 1998-12-16 | 2002-07-16 | Beiersdorf Ag | Biphenyl and biphenyl-analogous compounds as integrin antagonists |
| US6677360B2 (en) | 1998-12-16 | 2004-01-13 | Bayer Aktiengesellschaft | Biphenyl and biphenyl-analogous compounds as integrin antagonists |
| US6291503B1 (en) * | 1999-01-15 | 2001-09-18 | Bayer Aktiengesellschaft | β-phenylalanine derivatives as integrin antagonists |
| CN1589145A (zh) * | 1999-06-02 | 2005-03-02 | 麦克公司 | αv整联蛋白受体拮抗剂 |
| US6407241B1 (en) | 1999-11-08 | 2002-06-18 | Merck & Co., Inc. | Process and intermediates for the preparation of imidazolidinone αv integrin antagonists |
| US6455539B2 (en) * | 1999-12-23 | 2002-09-24 | Celltech R&D Limited | Squaric acid derivates |
| CA2397194C (en) | 2000-01-20 | 2011-05-17 | Mark E. Duggan | Alpha v integrin receptor antagonists |
| CA2397665A1 (en) | 2000-01-24 | 2001-07-26 | Merck & Co., Inc. | Alpha v integrin receptor antagonists |
| CN1366461A (zh) | 2000-02-22 | 2002-08-28 | 三得利株式会社 | 含有胃促胰酶抑制剂作为有效成分的预防或治疗纤维变性的药物 |
| GB0011817D0 (en) * | 2000-05-16 | 2000-07-05 | Pharmacia & Upjohn Spa | Antagonists of integrin receptors |
| AU7793501A (en) | 2000-07-26 | 2002-02-05 | Merck & Co Inc | Alpha v integrin receptor antagonists |
| WO2002022616A2 (en) | 2000-09-14 | 2002-03-21 | Merck & Co., Inc. | Alpha v integrin receptor antagonists |
| WO2002022615A1 (en) | 2000-09-14 | 2002-03-21 | Merck & Co., Inc. | Alpha v integrin receptor antagonists |
| EP1322311A1 (en) * | 2000-09-18 | 2003-07-02 | Merck & Co., Inc. | Treatment of inflammation with a combination of a cyclooxygenase-2 inhibitor and an integrin alpha-v antagonist |
| EP1444231A4 (en) | 2001-11-06 | 2005-11-09 | Merck & Co Inc | AMINO SALT OF AN INTEGRIN RECEPTOR ANTAGONIST |
| US20040053968A1 (en) | 2001-12-28 | 2004-03-18 | Hartman George D. | Methods and compositions for treating peridontal disease |
| EP1551401A4 (en) | 2002-09-20 | 2006-03-22 | Merck & Co Inc | MANNITOL FORMULATION FOR AN INTEGRIN RECEPTOR ANTAGONIST |
| EP1592421A1 (en) | 2002-12-20 | 2005-11-09 | Pharmacia Corporation | Heteroarylalkanoic acids as integrin receptor antagonists |
| ATE399542T1 (de) | 2003-10-01 | 2008-07-15 | Merck Patent Gmbh | Alfavbeta3 und alfavbeta6 integrin antagonisten als antifibrotische mittel |
| CN102026671B (zh) * | 2008-03-14 | 2014-09-03 | Visen医药公司 | 整联蛋白靶向试剂及使用其的体内和体外成像方法 |
| WO2011060395A1 (en) | 2009-11-16 | 2011-05-19 | Schering Corporation | Cyclic ureas useful as hiv inhibitors |
| US8969349B2 (en) | 2010-05-26 | 2015-03-03 | Sunovion Pharmaceuticals Inc. | Substituted quinoxalines and quinoxalinones as PDE-10 inhibitors |
| KR102165421B1 (ko) | 2011-05-09 | 2020-10-14 | 알레그로 파마슈티칼스, 인코포레이티드. | 인테그린 수용체 길항물질 및 이의 사용 방법 |
| CN103764118A (zh) | 2011-06-28 | 2014-04-30 | 拜尔健康护理有限责任公司 | 含有索拉非尼的局部眼用药用组合物 |
| US8901144B2 (en) | 2013-02-07 | 2014-12-02 | Scifluor Life Sciences, Llc | Fluorinated 3-(2-oxo-3-(3-arylpropyl)imidazolidin-1-yl)-3-arylpropanoic acid derivatives |
| PT2953948T (pt) * | 2013-02-07 | 2017-12-12 | Scifluor Life Sciences Inc | Antagonistas de integrina fluorada |
| US9790222B2 (en) * | 2015-02-19 | 2017-10-17 | Scifluor Life Sciences, Inc. | Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and uses thereof |
| BR112017023432A2 (pt) | 2015-04-30 | 2018-07-24 | Scifluor Life Sciences Inc | Derivados de ácido propiônico tetra- hidronaftiridinila e usos do mesmo |
| WO2018183795A1 (en) * | 2017-03-30 | 2018-10-04 | Scifluor Life Sciences, Inc. | Method of making tetrahydronaphthyridinyl nonanoic acid compounds |
-
2016
- 2016-02-19 US US15/047,717 patent/US9790222B2/en not_active Expired - Fee Related
- 2016-02-19 CA CA2976634A patent/CA2976634C/en active Active
- 2016-02-19 RU RU2017132433A patent/RU2017132433A/ru not_active Application Discontinuation
- 2016-02-19 WO PCT/US2016/018612 patent/WO2016134223A2/en not_active Ceased
- 2016-02-19 JP JP2017544035A patent/JP2018510139A/ja active Pending
- 2016-02-19 BR BR112017017888A patent/BR112017017888A2/pt not_active Application Discontinuation
- 2016-02-19 CN CN202210129062.7A patent/CN114805342A/zh active Pending
- 2016-02-19 EP EP21171386.2A patent/EP3925959A1/en not_active Withdrawn
- 2016-02-19 KR KR1020177026258A patent/KR102647026B1/ko active Active
- 2016-02-19 ES ES16753120T patent/ES2892954T3/es active Active
- 2016-02-19 EP EP16753120.1A patent/EP3259271B1/en active Active
- 2016-02-19 CN CN201680022826.5A patent/CN107531699A/zh active Pending
- 2016-02-19 AU AU2016219906A patent/AU2016219906B2/en not_active Ceased
- 2016-02-19 TW TW105104964A patent/TWI736529B/zh not_active IP Right Cessation
-
2017
- 2017-08-07 IL IL253873A patent/IL253873A0/en active IP Right Grant
- 2017-09-11 US US15/700,351 patent/US10301307B2/en active Active
-
2019
- 2019-04-03 US US16/373,780 patent/US20190225609A1/en not_active Abandoned
-
2020
- 2020-10-12 JP JP2020171641A patent/JP7191299B2/ja active Active
- 2020-10-22 US US17/076,891 patent/US11685738B2/en active Active
-
2023
- 2023-05-31 US US18/203,776 patent/US12286432B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| ES2892954T3 (es) | 2022-02-07 |
| AU2016219906A1 (en) | 2017-09-07 |
| WO2016134223A3 (en) | 2016-10-20 |
| CN114805342A (zh) | 2022-07-29 |
| WO2016134223A2 (en) | 2016-08-25 |
| IL253873A0 (en) | 2017-10-31 |
| JP2018510139A (ja) | 2018-04-12 |
| RU2017132433A3 (https=) | 2019-03-25 |
| JP7191299B2 (ja) | 2022-12-19 |
| KR20170117578A (ko) | 2017-10-23 |
| EP3259271A2 (en) | 2017-12-27 |
| US20240092775A1 (en) | 2024-03-21 |
| US20210277000A1 (en) | 2021-09-09 |
| JP2021008511A (ja) | 2021-01-28 |
| CA2976634C (en) | 2023-10-17 |
| US20160244447A1 (en) | 2016-08-25 |
| KR102647026B1 (ko) | 2024-03-12 |
| US12286432B2 (en) | 2025-04-29 |
| TW201643161A (zh) | 2016-12-16 |
| US11685738B2 (en) | 2023-06-27 |
| AU2016219906B2 (en) | 2020-10-01 |
| EP3925959A1 (en) | 2021-12-22 |
| US9790222B2 (en) | 2017-10-17 |
| CA2976634A1 (en) | 2016-08-25 |
| RU2017132433A (ru) | 2019-03-19 |
| US20170369490A1 (en) | 2017-12-28 |
| US10301307B2 (en) | 2019-05-28 |
| CN107531699A (zh) | 2018-01-02 |
| EP3259271B1 (en) | 2021-05-05 |
| US20190225609A1 (en) | 2019-07-25 |
| EP3259271A4 (en) | 2018-07-11 |
| TWI736529B (zh) | 2021-08-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112017017888A2 (pt) | derivados fluorados do ácido tetraidronaftiridinil nonanoico derivados e usos destes | |
| CY1120213T1 (el) | Antαγωνιστες φθοριωμενης ιντεγκρινης | |
| EA201591003A1 (ru) | Производные бороновой кислоты и их терапевтическое применение | |
| MX391180B (es) | Derivado de pirazolo-heteroarilo, metodo de preparacion y uso medico del mismo | |
| MX2020003415A (es) | Compuestos de benzoxacepina oxazolidinona y métodos de uso. | |
| BR112015016793A2 (pt) | compostos de tiazolacarboxamidas e piridinacarbo-xamida úteis como inibidores de quinase pim | |
| BR112015023948A2 (pt) | composto de fórmula (i), composição farmacêutica, método para o tratamento e/ou prevenção de uma doença proliferativa e para a inibição ou a diferenciação do crescimento de uma célula tronco do câncer | |
| MX383706B (es) | Composiciones de cenicriviroc y métodos para elaborarlas y usarlas. | |
| EA201790306A1 (ru) | 2-(морфолин-4-ил)-1,7-нафтиридины | |
| BR112017020837A2 (pt) | compostos de carbamoilpiridona policíclicos e seu uso farmacêutico | |
| BR112014027571A2 (pt) | métodos para o tratamento de retinopatia diabética e outras doenças oftalmológicas | |
| EA201590053A1 (ru) | Модуляторы пути системы комплемента и их применение | |
| BR112015021470A2 (pt) | conjugado de polímero para administração de um agente bioativo | |
| BR112017026132A2 (pt) | piridinas substituídas e métodos de uso | |
| BR112017009552A8 (pt) | Métodos para alvejar o controle transcricional em regiões de super-realçador | |
| BR112017010645A2 (pt) | derivados da piridinocarboxamida, método de preparação dos mesmos e usos farmacêuticos dos mesmos | |
| EA201590697A1 (ru) | Производные кетамина | |
| MX389600B (es) | Nueva composición terapéutica que contiene ingrediente activo de apomorfinas. | |
| EA201490045A1 (ru) | Дейтерированные 1-пиперазино-3-фенилинданы, применяемые для лечения шизофрении | |
| BR112015015250A2 (pt) | derivados de pirrolidina, composições farmacêuticas e usos dos mesmos | |
| EA201591653A1 (ru) | Композиции для лечения глазных расстройств с применением дипиридамола | |
| BR112016007526A8 (pt) | formulação de comprimido bicamada de dois fármacos antirretrovirais úteis contra o hiv, comprimido, seu método de produção e uso | |
| BR112015018200A2 (pt) | composição mastigável para administração oral e processo para preparar a mesma | |
| BR112015022290A2 (pt) | derivados de heterocíclicos benzo-fundidos úteis como agonistas de gpr120 | |
| EP4245295A3 (en) | Compounds and pharmaceutical compositions for use in treating retina-associated disease using ccr3-inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |